Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSI) Current Assets (2021 - 2026)

TriSalus Life Sciences has reported Current Assets over the past 6 years, most recently at $68.1 million for Q1 2026.

  • For Q1 2026, Current Assets rose 171.51% year-over-year to $68.1 million; the TTM value through Mar 2026 reached $68.1 million, up 171.51%, while the annual FY2025 figure was $32.2 million, 56.0% up from the prior year.
  • Current Assets for Q1 2026 was $68.1 million at TriSalus Life Sciences, up from $32.2 million in the prior quarter.
  • Over five years, Current Assets peaked at $68.1 million in Q1 2026 and troughed at $161454.0 in Q2 2023.
  • A 5-year average of $20.6 million and a median of $20.9 million in 2023 define the central range for Current Assets.
  • Biggest five-year swings in Current Assets: plummeted 39.4% in 2023 and later soared 17205.86% in 2024.
  • Year by year, Current Assets stood at $17.2 million in 2022, then rose by 21.19% to $20.9 million in 2023, then fell by 0.93% to $20.7 million in 2024, then surged by 56.0% to $32.2 million in 2025, then soared by 111.32% to $68.1 million in 2026.
  • Business Quant data shows Current Assets for TLSI at $68.1 million in Q1 2026, $32.2 million in Q4 2025, and $33.3 million in Q3 2025.